Pharmacologic approaches to radiation protection

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4084-4089

  Brizel, David M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; BENZYDAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; ISEGANAN; PACLITAXEL; PALIFERMIN; PLACEBO; SUCRALFATE; RADIOPROTECTIVE AGENT;

CANCER CONTROL; CANCER RADIOTHERAPY; CELL DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA STRAND BREAKAGE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHEMA MULTIFORME; ESOPHAGITIS; HUMAN; HYPERSALIVATION; HYPOTENSION; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MITOSIS; MUCOSA INFLAMMATION; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PALLIATIVE THERAPY; PEPTIC ULCER; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS; VOMITING; WHOLE BODY RADIATION; XEROSTOMIA; ANIMAL; METHODOLOGY; NEOPLASM;

ANIMALS; HUMANS; NEOPLASMS; RADIATION INJURIES; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS;

EID: 34748860378     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.5816     Document Type: Review

References (33)

1. Brizel DM, ed: Strategies for protecting normal tissue in the treatment of head and neck cancer, in Adelstein DJ, ed: Squamous Cell Head and Neck Cancer Recent Clinical Progress and Prospects for the Future. Totowa, NJ, Humana Press, 2005, pp 228
2. Yuhas JM, Spellman JM, Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3:211-216, 1980
3. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
4. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154, 2005
5. Koukourakis Ml, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
6. Boccia R, Anne PR, Bourhis J, et al: Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys 60:302-309, 2004
7. Lindegaard JC, Grau C: Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 57:113-118, 2000
8. Simon RM: Clinical Trials in Cancer, in DeVita H, Rosenberg (eds): Cancer Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 1997, pp 520-521
9. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
10. Bourhis JTH, Brizel DM, Movsas B, et al: Meta-Analysis of Amifostine in Radiotherapy (MAART): Preliminary analysis of 11 randomized clinical trials including 1,014 patients. Int J Radiat Oncol Biol Phys 66:S67, 2006
11. Movsas B: Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol 12:40-45, 2002 (suppl 1)
12. Vujaskovic Z, Thrasher B, Jackson IL, et al: Radioprotective effects of amifostine on acute and chronic esophengeal injury in a rodent model. Int J Radiat Oncol Bio Phys (in press)
13. Vujaskovic Z, Rabbani Z, Anscher MS, et al: Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res 28:577-590, 2002
14. Vujaskovic Z, Feng QF, Rabbani ZN, et al: Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity. Radiat Res 157:656-660, 2002
15. Antonadou D, Pepelassi M, Synodinou M, et al: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747, 2002
16. Büntzel J, Glatzel M, Kuttner K, et al: Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 12:4-13, 2002
17. Potten CS, O'Shea JA, Farrell CL, et al: The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine. Cell Growth Differ 12:265-275, 2001
18. Dörr W, Spekl K, Farrell CL: Amelioration of acute oral mucositis by keratinocyte growth factor: Fractionated irradiation. Int J Radiat Oncol Biol Phys 54:245-251, 2002
19. Dörr W, Spekl K, Farrell CL: The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 35:86-92, 2002 (suppl 1)
20. Chen L, Brizel DM, Rabbani ZN, et al: The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int J Radiat Oncol Biol Phys 60:1520-1529, 2004
21. Spielberger R, Stiff P, Bensinger W, et al: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590-2598, 2004
22. Brizel DM, Herman T, Goffinet D, et al: A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CCT). Int J Radiat Oncol Biol Phys 51:40, 2001 (suppl)
23. Zia-Amirhosseini P, Salfi M, Leese P, et al: Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 79:558-569, 2006
24. Martin F, Farley A, Gagnon M, et al: Comparison of the healing capacities of sucralfate and cimetidine in the short-term treatment of duodenal ulcer: A double-blind randomized trial. Gastroenterology 82:401-405, 1982
25. Carter DL, Hebert ME, Smink K, et al: Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. Head Neck 21:760-766, 1999
26. Makkonen TA, Bostrom P, Vilja P, et al: Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 30:177-182, 1994
27. Meredith R, Salter M, Kim R, et al: Sucralfate for radiation mucositis: Results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 37:275-279, 1997
28. 2a Pfeiffer P, Madsen EL, Hansen O, et al: Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy: A randomized, double-blind crossover study. Acta Oncol 29:171-173, 1990
29. Segre G, Hammarstrom S: Aspects of the mechanisms of action of benzydamine. Int J Tissue React 7:187-193, 1985
30. Sironi M, Pozzi P, Polentarutti N, et al: Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 8:710-716, 1996
31. Epstein JB, Silverman S Jr, Paggiarino DA, et al: Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92:875-885, 2001
32. Bellm L, Lehrer Rl, Ganz T: Protegrins: New antibiotics of mammalian origin. Expert Opin Investig Drugs 9:1731-1742, 2000
33. Trotti A, Garden A, Warde P, et al: A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58:674-681, 2004